Frontiers Lu-177-PSMA dosimetry for kidneys and tumors based on

TP53 loss renders PCa resistant to PSMA RLT. (A) Tumor growth of C4-2

Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy

Cancers, Free Full-Text

Frontiers 177Lu-labeled PSMA targeting therapeutic with

Cancers, Free Full-Text

Practical Guidance on [177Lu]Lu-PSMA-617 Treatment, Including

Radiation Dosimetry in 177Lu-PSMA-617 Therapy - ScienceDirect

Fibroblast activation protein-based theranostics in cancer

Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy

Lutetium-177 prostate-specific membrane antigen (PSMA

Theranostics and artificial intelligence: new frontiers in